Fleisher L D, Rassin D K, Wisniewski K, Salwen H R
Pediatr Res. 1980 Apr;14(4 Pt 1):269-71. doi: 10.1203/00006450-198004000-00001.
Plasma carnosinase deficiency was discovered in a 12-yr-old male with profound mental retardation, severe athetoid spastic quadriparesis, optic atrophy, sensory peripheral neuropathy, and suprabulbar signs. Amino acid analysis revealed persistent carnosinuria but no detectable carnosinemia. After ingestion of L-carnosine (100 mg/kg), the patient had carnosine in his plasma and excreted 28% of the administered load as carnosine (an agematched control excreted 1.3% as carnosine). Urinary 1-methylhistidine was measurable in the patient and increased greatly during a high anserine diet. Plasma carnosinase activity in the patient was 0.28 mumoles per ml plasma per hr (control mean, 2.00; range, 1.10--2.85), his parents had activity of 1.36 and 1.30, and 2 sibs had activities of 1.10 and 1.86. Carnosinase activity in liver from the patient was 43% of control liver. We have demonstrated that carnosinase activity is present in human nerve and that sural nerve from the patient had activity that was 46% of control nerve. Histopathologic examination of the patient's nerve showed axonal degeneration. Histidine levels in the patient's liver and nerve were normal, and neither beta-alanine nor carnosine was detectable. The unusually high residual carnosinase activity in plasma and tissues from this patient may explain his apparent ability to metabolize anserine and would suggest that this represents a new variant form of carnosinase deficiency. Speculation. Carnosinuria due to plasma carnosinase deficiency may be merely associated with the strinking neurologic findings that have been reported rather than causally related.
在一名12岁男性患者中发现了血浆肌肽酶缺乏症,该患者有严重智力发育迟缓、严重手足徐动型痉挛性四肢瘫、视神经萎缩、感觉性周围神经病和脑桥上部体征。氨基酸分析显示持续性肌肽尿症,但未检测到血浆肌肽。摄入L-肌肽(100mg/kg)后,患者血浆中出现肌肽,并以肌肽形式排出给药量的28%(一名年龄匹配的对照者以肌肽形式排出1.3%)。患者尿液中可检测到1-甲基组氨酸,在高鹅肌肽饮食期间显著增加。患者血浆肌肽酶活性为每毫升血浆每小时0.28微摩尔(对照平均值为2.00;范围为1.10 - 2.85),其父母的活性分别为1.36和1.30,两名同胞的活性分别为1.10和1.86。患者肝脏中的肌肽酶活性为对照肝脏的43%。我们已经证明人类神经中存在肌肽酶活性,该患者的腓肠神经活性为对照神经的46%。患者神经的组织病理学检查显示轴突变性。患者肝脏和神经中的组氨酸水平正常,未检测到β-丙氨酸和肌肽。该患者血浆和组织中异常高的残余肌肽酶活性可能解释了他代谢鹅肌肽的明显能力,这表明这代表了一种新的肌肽酶缺乏变异形式。推测。由于血浆肌肽酶缺乏导致的肌肽尿症可能仅与已报道的显著神经系统表现相关,而非因果关系。